Welcome to
BGI Australia

BGI Genomics and a digital health start-up, Pryzm Health (Pryzm), signed a Memorandum of Understanding on 14 May 2019 for collaboration to advance precision public health in Australia. With their complementary expertise and technology, BGI Genomics and Pryzm will develop foundational capabilities to drive equitable access to precision medicine approaches across the health system. This movement, termed precision public health, will enable more rapid diagnoses, improved efficiency, better patient outcomes and more economically-sustainable health practices. Pryzm is an innovative digital health start-up focused on guiding personal and clinical health decisions by accelerating diagnosis of rare and inherited diseases. The collaboration aims to improve the utility of cost-effective genomic testing for the clinic and lower the barriers for access to precision healthcare in Australia by harnessing the synergy between the complementary technologies of BGI Genomcs in genomics and Pryzm in the integration and analytics of genomic information and electronic health data. BGI Genomics, a subsidiary of BGI, provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. 

genomiQa and BGI Genomics formed an agreement, on 25 March, on clinical whole genome cancer sequencing utilising BGI’s ISO15189 accredited laboratory sequencing facilities. Dr Bicheng Yang, Director of BGI Australia said, “We are really pleased with the growth of our sequencing services on DNBseqTM technology platform, and the opportunity to support innovative companies like genomiQa. By working together with genomiQa, researchers and physicians can use whole genome analysis to unlock potential new treatments and support the best patient outcomes similar to the “Immunotherapy Outcomes Predication” project we are working together on." genomiQa's CEO Colin Albert said “We have been working with BGI on a number of research projects and validation studies to reach this exciting milestone. More importantly we will start to help patients who have only had access to comprehensive panels, where up to 38%1 of breast cancer patients may not have received the best treatment options, as actionable information was not available’’. genomiQa also intends to use BGI’s facility in Australia, once it has completed the ISO 15189 accreditation process, which is anticipated within the next 12 months. Keep reading

BGI-Research and the Macquarie University of Australia formally signed a cooperation agreement during the 7th International Yeast 2.0 and Synthetic Genomes Conference 2018 in Sydney, on 26th November. The two sides will jointly promote scientific research and education in synthetic biology, and focus on engineering bacteria transformation of natural products in synthetic biology. In the next five years, BGI Research and Macquarie University will fully leverage their resources to focus on bilateral cooperation in the fields of synthetic biology, metabolic engineering, and natural product synthesis. The two parties will work together with the goal to jointly opening new channels for talent training, to explore opportunities for industrialization of scientific research projects and drive related areas development in China and Australia. Keep reading

A Memorandum of Understanding (MOU) between a global leader in genomics and gene sequencing BGI and Xing Technologies is signed on 22 Aug 2018 supporting collaborative research and product innovation in the following areas: DNB technology: optimise current DNA nanoball technology to improve sequencing data quality and throughput resulting in reduced sequencing costs;

Point-of-care product: based on XING’s patented “Laboratory in a Drop” technology, undertake joint research into, and manufacturing of, a transformative diagnostic product developed by XING to offer the world, including millions of Australians, an accurate, rapid and inexpensive point-of-care disease screening, diagnosis & monitoring kit, which will revolutionise current practice. The applications even extend to human health as well as animals and plant material, such as agriculture, aquaculture, veterinary science.